"Often, the break-even of a drug is only reached in the last month or weeks of patent duration. Taking this into account, it does not seem unfair that big pharma companies use the possibilities that the European patent system offers. The first offer is for such a European system not to exist at all. After the initial filing of a patent to the European Patent Office, the patent itself is transferred to a jungle-like system of national regulations, making a clear cut after the end of the patent duration impossible. The amount of money spent by the originator as well as generic companies is outrageous. […] It drives both sides away from their core business and delays generic medicines, resulting in a severe cost burden for our health systems. The Commission should now do the only right thing. It should not start the blame game; it should not condemn big pharma for a legitimate strategy. It should start the process of reforming the European patent system. A reform, which would be close to a revolution. A key could be to trade off longer patent duration against bureaucratic hurdles. A clear and simple system could provide legal certainty for all parties involved and contribute to a better and obstacle-free cooperation between pharmaceutical companies, benefiting both the originator and the generics - and also the most important group: the patients."